# Immix rises after mid-stage trial data for AL amyloidosis therapy.

*biotech · news · 2026-05-21 · Seeking Alpha*

## Key points

- Immix Biopharma announced mid-stage trial data for NXC-201 in AL amyloidosis.
- NXC-201 is being tested for a rare disease involving abnormal light chain accumulation.
- Following the announcement, Immix Biopharma's stock price rose.
- Specific details of the mid-stage trial data were not disclosed in the announcement.

Immix rises after mid-stage trial data for AL amyloidosis therapy May 21, 2026, 7:02 AM ETImmix Biopharma, Inc. (IMMX) StockBy : Dulan Lokuwithana, SA News Editor Comment (1) Immix Biopharma (IMMX) traded higher after announcing data from a mid-stage trial for its lead asset, NXC-201, in AL amyloidosis, a rare disease characterized by the accumulation of abnormal light chains in various organs of the body. The company said Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4595696-immix-rises-data-al-amyloidosis-therapy)

---

Canonical: https://newsio.io/n/2a3c5859-09b9-4b94-85ae-62bd356fd4e1/immix-rises-after-mid-stage-trial-data-for-al-amyloidosis-therapy
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works